Anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy is emerging as a promising option for relapsed myeloma patients; however, most clinical trials of CAR T therapy for MM were paused during the pandemic because of the possibility of increased morbidity and mortality with COVID-19. Here, TNFRSF17 is linked to plasma cell myeloma.